Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2018 07:00 ET | Source: Leap Therapeutics, Inc.

Leap Therapeutics Reports Second Quarter 2018 Business Update and Financial Results

CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported a business...
July 23, 2018 07:30 ET | Source: Leap Therapeutics, Inc.

Leap Therapeutics Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Combination of TRX518, Avelumab, and Chemotherapy in Advanced Solid Tumors

CAMBRIDGE, Mass., July 23, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced it has...
June 13, 2018 07:00 ET | Source: Leap Therapeutics, Inc.

Leap Therapeutics to Present at the 2018 JMP Securities Life Sciences Conference

CAMBRIDGE, Mass., June 13, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that...
May 11, 2018 07:00 ET | Source: Leap Therapeutics, Inc.

Leap Therapeutics Reports First Quarter 2018 Financial Results

CAMBRIDGE, Mass., May 11, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial...
April 16, 2018 09:00 ET | Source: Leap Therapeutics, Inc.

Leap Therapeutics Presents Nonclinical and Clinical Data on DKN-01 at AACR 2018 Annual Meeting

CAMBRIDGE, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today presented nonclinical and clinical data on DKN-01, Leap’s anti-DKK1 monoclonal antibody, at the...
March 27, 2018 16:05 ET | Source: Leap Therapeutics, Inc.

Leap Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

CAMBRIDGE, Mass., March 27, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...
March 23, 2018 09:00 ET | Source: Leap Therapeutics, Inc.

Leap Therapeutics Announces Pricing of $14 Million Public Offering of Common Stock

CAMBRIDGE, Mass., March 23, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...
March 22, 2018 16:05 ET | Source: Leap Therapeutics, Inc.

Leap Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., March 22, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...
March 21, 2018 07:00 ET | Source: Leap Therapeutics, Inc.

Leap Therapeutics to Present at the 2018 Needham & Company 17th Annual Healthcare Conference

CAMBRIDGE, Mass., March 21, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that...
March 14, 2018 17:00 ET | Source: Leap Therapeutics, Inc.

Leap Therapeutics Provides DKN-01 Program Update and Announces Scientific Presentations at AACR Annual Meeting

CAMBRIDGE, Mass., March 14, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today presented promising...